Skip to main content

Table 1 Patients characteristics

From: A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites

  

All

(N = 83) (%)

No ascites

(N = 43) (%)

Small to moderate ascites

(N = 26) (%)

Massive ascites

(N = 14) (%)

Age

Median (range)

67 (23–83)

68 (48–78)

64.5 (23–83)

67.5 (32–81)

Gender

Male*

60 (72)

37 (86)

15 (58)

8 (57)

ECOG PS

0*

48 (58)

28 (65)

18 (69)

2 (14)

1

25 (30)

13 (30)

5 (19)

7 (50)

2*

10 (12)

2 (5)

3 (12)

5 (36)

Histological Type

Diffuse

47 (57)

20 (46)

17 (65)

10 (71)

Intestinal

36 (43)

23 (54)

9 (35)

4 (29)

Number of previous CTX

1

59 (71)

29 (67)

18 (69)

12 (86)

≥2

24 (29)

14 (33)

8 (31)

2 (14)

Gastrectomy

Yes

31 (37)

18 (42)

7 (27)

6 (43)

Target lesion

Yes

45 (54)

28 (65)

12 (46)

5 (36)

Site of metastasis

Lymph node

56 (67)

34 (79)

15 (58)

7 (50)

Liver

22 (27)

13 (30)

7 (27)

2 (14)

Peritoneal

49 (59)

11 (26)

24 (92)

14 (100)

Ovary*

10 (12)

1 (2)

5 (19)

4 (29)

Number of metastases

1–2*

70 (84)

39 (91)

19 (73)

12 (86)

≥ 3

13 (16)

4 (9)

7 (27)

2 (14)

  1. CTX chemotherapy
  2. *p < 0.05